Research Analysts Offer Predictions for GYRE Q3 Earnings

Key Points

• HC Wainwright has issued a Q3 2025 earnings estimate for Gyre Therapeutics, projecting earnings per share of $0.07 and maintaining a "Buy" rating with a price target of $18.00.
• Gyre Therapeutics recently reported Q2 earnings of $0.02 per share, missing estimates, along with a revenue of $26.77 million, below the expected $30.80 million.
• Institutional investors have significantly increased their stakes in Gyre Therapeutics, with Bank of America and JPMorgan Chase boosting their holdings by 28.8% and 84.6%, respectively.

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) - Stock analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Gyre Therapeutics in a research note issued on Tuesday, August 26th. HC Wainwright analyst M. Keller forecasts that the company will earn $0.07 per share for the quarter. HC Wainwright has a "Buy" rating and a $18.00 price target on the stock. HC Wainwright also issued estimates for Gyre Therapeutics' Q4 2025 earnings at $0.06 EPS, FY2025 earnings at $0.17 EPS, FY2026 earnings at $0.04 EPS and FY2027 earnings at ($0.09) EPS.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). The company had revenue of $26.77 million for the quarter, compared to analysts' expectations of $30.80 million. Gyre Therapeutics had a net margin of 4.08% and a return on equity of 7.67%.

Gyre Therapeutics Trading Down 0.1%

Gyre Therapeutics stock traded down $0.01 during mid-day trading on Thursday, hitting $7.74. The stock had a trading volume of 34,522 shares, compared to its average volume of 161,857. The firm's 50 day moving average is $7.58 and its 200 day moving average is $8.79. Gyre Therapeutics has a one year low of $6.11 and a one year high of $19.00. The firm has a market capitalization of $744.96 million, a P/E ratio of 774.27 and a beta of 1.86.

Institutional Trading of Gyre Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its stake in shares of Gyre Therapeutics by 28.8% during the second quarter. Bank of America Corp DE now owns 6,277 shares of the company's stock valued at $46,000 after acquiring an additional 1,402 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company's stock valued at $47,000 after acquiring an additional 2,961 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Gyre Therapeutics by 29.4% during the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock valued at $49,000 after acquiring an additional 913 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Gyre Therapeutics by 77.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company's stock valued at $54,000 after acquiring an additional 3,244 shares in the last quarter. Finally, Advantage Alpha Capital Partners LP raised its stake in shares of Gyre Therapeutics by 54.0% during the first quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company's stock valued at $105,000 after acquiring an additional 4,790 shares in the last quarter. Institutional investors own 23.99% of the company's stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.